# A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

> **NCT05817435** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 120 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC as a prefilled syringe presentation
- **BIOLOGICAL:** efgartigimod PH20 SC as a vial + syringe presentation

## Key facts

- **NCT ID:** NCT05817435
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-13
- **Primary completion:** 2023-05-12
- **Final completion:** 2023-05-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817435, "A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05817435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*